Literature DB >> 923183

Bioavailability and first-pass metabolism of oral pentazocine in man.

M Ehrnebo, L O Boréus, U Lönroth.   

Abstract

The bioavailability of oral pentazocine was studied in 5 healthy volunteers. Plasma concentrations were determined from 30 min up to 6 hr following oral administration (two 50-mg tablets) and, at other occasions, after intravenous injection of 30 mg pentazocine. The average bioavailability was found to be 18.4 +/- 7.8% (SD, n = 5). It is shown that this low bioavailability depend almost entirely on the first-pass metabolism of pentazocine following oral administration by application of intravenous clearance concepts. The average beta-phase half-life was about the same following intravenous administration, 203 +/- 71 (SD, n = 5) min as following oral administration, 177 +/- 34 (SD, n = 5) min, with a total volume of distribution of 5.56 +/- 1.63 (SD, n = 5) L/kg. It is suggested that the variations in bioavailability of orally administered pentazocine have the potential to contribute to variations in pharmacologic effects in patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 923183     DOI: 10.1002/cpt1977226888

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

1.  [Not Available].

Authors:  J Radke; E Turner; D Kettler
Journal:  Schmerz       Date:  1990-12       Impact factor: 1.107

Review 2.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

3.  The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.

Authors:  M W Lo; F H Lee; W L Schary; C C Whitney
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 4.  Pharmacokinetics in intravenous anaesthetic practice.

Authors:  P Duvaldestin
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

5.  Parenteral pentazocine: effects on psychomotor skills and respiration, and interactions with amitriptyline.

Authors:  U Saarialho-Kere; M J Mattila; T Seppälä
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of narcotic agonist-antagonist drugs.

Authors:  R E Bullingham; H J McQuay; R A Moore
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

7.  Prediction of the volumes of distribution of basic drugs in humans based on data from animals.

Authors:  Y Sawada; M Hanano; Y Sugiyama; H Harashima; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

Review 8.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

10.  Pharmacokinetics of the new analgesic, meptazinol, after oral and intravenous administration to volunteers.

Authors:  H M Norbury; R A Franklin; D F Graham
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.